AstraZeneca and the University of Oxford have announced positive high-level results from an interim analysis of clinical trials of its COVID-19 vaccine candidate, AZD1222, in the U.K. and Brazil, ...
RIO DE JANEIRO (Reuters) - Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or ...
Hosted on MSN
Mystery of rare blood clots after COVID vaccines finally solved after years-long scientific quest
After years of work, scientists have solved the mystery of an unusual side effect that impacted some recipients of the Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines. Most importantly, the ...
(Reuters) - Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca after the drugmaker commissioned more batches from the company in the ...
The vaccine has 63.09% efficacy and is suitable for low- and middle-income countries. The organisation gave the green light for the vaccines on Monday, February 15, 2021 ending a wait to have them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results